Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Arthritis Rheumatol ; 69(7): 1480-1494, 2017 07.
Article in English | MEDLINE | ID: mdl-28296284

ABSTRACT

OBJECTIVE: Systemic-onset juvenile idiopathic arthritis (JIA) is speculated to follow a biphasic course, with an initial systemic disease phase driven by innate immune mechanisms and interleukin-1ß (IL-1ß) as a key cytokine and a second chronic arthritic phase that may be dominated by adaptive immunity and cytokines such as IL-17A. Although a recent mouse model points to a critical role of IL-17-expressing γ/δ T cells in disease pathology, in humans, both the prevalence of IL-17 and the role of IL-17-producing cells are still unclear. METHODS: Serum samples from systemic JIA patients and healthy pediatric controls were analyzed for the levels of IL-17A and related cytokines. Whole blood samples were studied for cellular expression of IL-17 and interferon-γ (IFNγ). CD4+ and γ/δ T cells isolated from the patients and controls were assayed for cytokine secretion in different culture systems. RESULTS: IL-17A was prevalent in sera from patients with active systemic JIA, while both ex vivo and in vitro experiments revealed that γ/δ T cells overexpressed this cytokine. This was not seen with CD4+ T cells, which expressed strikingly low levels of IFNγ. Therapeutic IL-1 blockade was associated with partial normalization of both cytokine expression phenotypes. Furthermore, culturing healthy donor γ/δ T cells in serum from systemic JIA patients or in medium spiked with IL-1ß, IL-18, and S100A12 induced IL-17 overexpression at levels similar to those observed in the patients' cells. CONCLUSION: A systemic JIA cytokine environment may prime γ/δ T cells in particular for IL-17A overexpression. Thus, our observations in systemic JIA patients strongly support a pathophysiologic role of these cells, as proposed by the recent murine model.


Subject(s)
Arthritis, Juvenile/immunology , Interleukin-17/immunology , T-Lymphocytes/immunology , Adaptive Immunity/immunology , Adolescent , Adult , Antibodies, Monoclonal/therapeutic use , Antibodies, Monoclonal, Humanized , Antirheumatic Agents/therapeutic use , Arthritis, Juvenile/drug therapy , CD4-Positive T-Lymphocytes/immunology , Case-Control Studies , Chemokine CXCL10/immunology , Chemokine CXCL9/immunology , Child , Child, Preschool , Cytokines/immunology , Female , Humans , Immunity, Innate/immunology , Interferon-gamma/immunology , Interleukin 1 Receptor Antagonist Protein/therapeutic use , Interleukin-18/immunology , Interleukin-18/pharmacology , Interleukin-1beta/immunology , Interleukin-1beta/pharmacology , Interleukin-23 Subunit p19/immunology , Interleukin-6/immunology , Male , Receptors, Antigen, T-Cell, gamma-delta/metabolism , S100A12 Protein/immunology , S100A12 Protein/pharmacology , T-Lymphocytes/metabolism , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...